Pharmacological treatment of borderline personality disorder

Journal of Psychiatric Intensive Care

Volumn 1, Issue 2, 2005, Pages 105-116

  Paton, Carol ^a   Okocha, Chike ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Bracton Centre   (United States)

Author keywords

BPD; PICUs; RCTs; SSRIs

Indexed keywords

EID: 85011497700     PISSN: 17426464     EISSN: 17422206     Source Type: Journal    
DOI: 10.1017/S1742646406000173     Document Type: Article

References (71)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edition). APA, Washington DC.
2. American Psychiatric Association (2001) Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry. 158: 1-52.
3. Baer, L. Jenike, M.A. Black, D.W. et al. (1992) Effect of axis 11 diagnoses on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Archives of General Psychiatry. 49: 862-866.
4. Benedetti, F. Sforzini, L. Colombo, C. et al. (1998) Low dose clozapine in acute and continuation treatment of severe borderline personality disorder. Journal of Clinical Psychiatry. 59: 103-107.
5. Bolton, S. and Gunderson, J.G. (1996) Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications. American Journal of Psychiatry. 153: 1202-1207.
6. Bonnet, K.A. and Redford, H.R. (1982) Levodopa in borderline doisorders. Archives of General Psychiatry. 39: 826.
7. Cheng, A.T.A. Mann, A.H. and Chan, K.A. (1997) Personality disorder and suicide: a case control study. British Journal of Psychiatry. 170: 441-446.
8. Chengappa, K.N.R. Ebeling, T. Kang, J.S. et al. (1999) Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. Journal of Clinical Psychiatry. 60: 477-484.
9. Coccaro, E.F. and Kavoussi, R.J. (1997) Fluoxetine and impulsive aggressive behaviour in personality disordered subjects. Archives of General Psychiatry. 54: 1081-1088.
10. Cornelius, J.R. Soloff, P.H. Perel, J.M. et al. (1990) Fluoxetine trial in borderline personality disorder. Psychopharmacology Bulletin. 26: 151-154.
11. Cornelius, J.R. Soloff, P.H. Perel, J. et al. (1993) Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry. 150: 1843-1848.
12. Cowdry, R.W. and Gardner, D.L. (1988) Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine and tranylcypromine. Archives of General Psychiatry. 45: 111-119.
13. DeBattista, C. and Mueller, K. (2001) Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder. The Journal of ECT. 17: 91-98.
14. De la Fuente, J.M. and Blotstra, F. (1994) A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology. 4: 479-486.
15. Deltito, J. Martin, L. Riefkohl, B. et al. (2001) Do patients with borderline personality disorder belong to the bipolar spectrum? Journal of Affective Disorders. 67: 221-228.
16. Faltus, F.J. (1984) The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. American Journal of Psychiatry. 141: 802-803.
17. Frankenburg, F.R. and Zanarini, M.C. (1993) Clozapine treatment of borderline patients: a preliminary study. Comprehensive Psychiatry. 34: 402-405.
18. Frankenburg, F.R. and Zanarini, M.C. (2002) Divalproex sodium treatment of women with borderline personality disorder and bipolar 11 disorder: a double blind, placebo controlled pilot study. Journal of Clinical Psychiatry. 63: 442-446.
19. Gardner, D.L. and Cowdry, R.W. (1986) Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology. 6: 236-239.
20. Gardner, D.L. and Cowdry, R.W. (1986) Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. American Journal of Psychiatry. 143: 519-522.
21. Gardner, D.L. and Cowdry, R.W. (1985) Alprazolaminduced dyscontrol in borderline personality disorder. American Journal of Psychiatry. 142: 98-100.
22. Goldberg, S.C. Schulz, C. Schulz, P. et al. (1986) Borderline and schizotypal personality disorders treated with low dose thiothixene vs placebo. Archives of General Psychiatry. 43: 680-686.
23. Goldberg, S.C. (1989) Prediction of change in borderline personality disorder. Psychopharmacology Bulletin. 25: 550-555.
24. Gunderson, J.G. Carpenter, W.T. and Strauss, J.S. (1975) Borderline and schizotypal patients: a comparative study. American Journal of Psychiatry. 132: 1257-1264.
25. Hedberg, D.L. Houck, J.H. and Glueck, B.C. (1971) Tranylcypromine — Trifluoperazine combination in the treatment of schizophrenia. American Journal of Psychiatry. 127: 1141-1146.
26. Hollander, E. Allen, A. Lopez, R.P. et al. (2001) A preliminary double-blind, placebo controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry. 62: 199-203.
27. Kavoussi, R.J. Liu, J. and Coccaro, E.F. (1994) An open trial of sertraline in personality disordered patients with impulsive aggression. Journal of Clinical Psychiatry. 55: 137-141.
28. Kavoussi, R.J. and Coccaro, E.F. (1998) Divalproex sodium for impulsive aggressive behaviour in patients with personality disorder. Journal of Clinical Psychiatry. 59: 676-680.
29. Kendell, R.E. (2002) The distinction between personality disorder and mental illness. British Journal of Psychiatry. 180: 110-115.
30. Klein, D.F. and Oaks, G. (1967) Importance of Psychiatric Diagnosis in prediction of clinical drug effects. Archives General Psychiatry. 16: 118-126.
31. Koenigsberg, H.W. Harvey, P.D. Mitropoulou, V. et al. (2002) Characterising affective instability in borderline personality disorder. American Journal of Psychiatry. 159: 784-788.
32. Leone, N.F. (1982) Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry. 43: 148-150.
33. Lewis, G. and Appleby, L. (1988) Personality disorder: the patients psychiatrists dislike. British Journal of Psychiatry. 153: 44-49.
34. Links, P.S. Steiner, M. Boiago, I. et al. (1990) Lithium therapy for borderline patients: preliminary findings. Journal of Personality Disorders. 4: 173-181.
35. Links, P.S. Heslegrave, R. and van Reekum, R. (1998) Prospective follow-up study of borderline personality disorder: prognosis, prediction of outcome and Axis II comorbidity. Canadian Journal of Psychiatry. 43: 265-270.
36. Markovitz, P.J. Calabrese, J.R. Schulz, S.C. et al. (1991) Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry. 148: 1064-1067.
37. Markovitz, P.J. and Wagner, S.C. (1995) Venlafaxine in the treatment of borderline personality disorder. Psychopharmacology Bulletin. 31: 773-777.
38. Miller, S.G. (1994) Borderline personality disorder from the patients perspective. Hospital & Community Psychiatry. 45: 1215-1219.
39. Montgomery, S.A. and Montgomery, D. (1982) Pharmacological prevention of suicidal behaviour. Journal of Affective Disorders. 4: 291-298.
40. Paris, J. (2002) Chronic suicidality among patients with borderline personality disorder. Psychiatric Services. 53: 738-742.
41. Paris, J. (2002) Commentary on the American Psychiatric Association guidelines for the treatment of borderline personality disorder: evidence based psychiatry and the quality of evidence. Journal of Personality Disorders. 16: 130-134.
42. Parsons, B. Quitkin, F.M. McGrath, P.J. et al. (1989) Phenelzine, imipramine and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacology Bulletin. 25: 524-534.
43. Pinto, O.C. and Akiskal, H.S. (1998) Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. Journal of Affective Disorders. 51: 333-343.
44. Rifkin, A. Quitkin, F. Carrillo, C. et al. (1972) Lithium carbonate in emotionally unstable character disorder. Archives of General Psychiatry. 27: 519-523.
45. Rinne, T. van der Brink, W. Wooters, L. et al. (2002) SSRI treatment of borderline personality disorder: a randomised, placebo controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry. 159: 2048-2054.
46. Rocca, P. Marchiavo, L. Cocuzza, E. et al. (2002) Treatment of borderline personality disorder with risperidone. Journal of Clinical Psychiatry. 63: 241-244.
47. Salzman, C. Wolfson, A.N. Schatzberg, A. et al. (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology. 15: 23-29.
48. Sanderson, C. Swenson, C. and Botus, M. (2002) A critique of the American Psychiatric Association practice guideline for the treatment of patients with borderline personality disorder. Journal of Personality Disorders. 16: 122-129.
49. Schulz, S.C. Camlin, K.L. Berry, S.A. et al. (1999) Olanzapine safety & efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry. 46: 1429-1435.
50. Schwartz, M. Blazer, D. George, L. et al. (1990) Estimating the prevalence of borderline personality disorder in the community. Journal of Personality Disorder. 4: 257-272.
51. Schulz, S.C. Cornelius, J. Schulz, P.M. et al. (1988) The amphetamine challenge test in patients with borderline personality disorder. American Journal of Psychiatry. 147: 809-814.
52. Serban, G. and Siegel, S. (1984) Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry. 141: 1455-1458.
53. Shawcross, C.R. and Tyrer, P. (1985) Influence of personality on response to monoamine oxidase inhibitors and tricyclic antidepressants. Journal of Psychiatry Research. 19: 557-562.
54. Shea, M.T. Pilkonis, P.A. Beckham, E. et al. (1990) Personality disorders and treatment outcome in the NIMH treatment of depression collaborative research program. American Journal of Psychiatry. 147: 711-718.
55. Soloff, P.H. Anselm, G. Nathan, R.S. et al. (1986) Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol and placebo. Archives of General Psychiatry. 43: 691-697.
56. Soloff, P.H. George, A. Nathan, S. et al. (1986) Paradoxical effects of amitriptyline in borderline patients. American Journal of Psychiatry. 143: 1603-1605.
57. Soloff, P.H. George, P.H. Nathan, R.S. et al. (1989) Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. Journal of Clinical Psychopharmacology. 9: 238-246.
58. Soloff, P.H. Cornelius, J. George, A. et al. (1993) Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry 50: 377-385.
59. Stein, D.J. Simeon, D. Frenkel, M. et al. (1995) An open trial of valproate in borderline personality disorder. Journal of Clinical Psychiatry. 56: 506-510.
60. Stevenson, J. Meares, R. and Comerford, A. (2003) Diminished impulsivity in older patients with borderline personality disorder. American Journal of Psychiatry. 160: 165-166.
61. Teicher, M.H. Glod, C.A. Aaronson, S.T. et al. (1989) Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacology Bulletin. 25: 535-549.
62. Tyrer, P. (2002) Practice guideline for the treatment of borderline personality disorder: a bridge too far. Journal of Personality Disorders. 16: 113-118.
63. Verhoeven, W. and Tuinier, S. (1997) Biological and psychopharmacological aspects of impulse-control disorders. Acta Neuropsychiatrica. 9: 89-93.
64. Vilkin, M.I. (1964) Comparative chemotherapeutic trial in treatment of chronic borderline patients. American Journal of Psychiatry. 120: 1004.
65. Winston, A.P. (2000) Recent developments in borderline personality disorder. Advances in Psychiatric Treatment. 6: 211-218.
66. World Health Organisation (1992) The ICD 10 classification of mental and behavioural disorders — clinical descriptions and diagnostic guidelines. WHO, Geneva.
67. Zanarini, M.C. and Frankenburg, F.R. (1997) Pathways to the development of borderline personality disorder. Journal of Personality Disorders. 11: 93-104.
68. Zanarini, M.C. Frankenburg, F.R. Dubo, E.D. et al. (1998) Axis 1 comorbidity of borderline personality disorder. American Journal of Psychiatry. 155: 1733-1739.
69. Zanarini, M.C. and Frankenburg, F.R. (2001) Olanzapine treatment of female borderline personality disorder patients: a double blind, placebo controlled pilot study. Journal of Clinical Psychiatry. 62: 849-854.
70. Zanarini, M.C. Frankenburg, F.R. Khera, J.S. et al. (2001) Treatment histories of borderline patients. Comprehensive Psychiatry. 42: 144-150.
71. Zanarini, M.C. and Frankenburg, F.R. (2003) Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. American Journal of Psychiatry. 160: 167-169.